These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 8186175

  • 1. Limited sampling models for topotecan pharmacokinetics.
    van Warmerdam LJ, Verweij J, Rosing H, Schellens JH, Maes RA, Beijnen JH.
    Ann Oncol; 1994 Mar; 5(3):259-64. PubMed ID: 8186175
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
    van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Bokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH.
    Cancer Chemother Pharmacol; 1996 Mar; 38(3):254-60. PubMed ID: 8646800
    [Abstract] [Full Text] [Related]

  • 3. Limited sampling model for area under the concentration time curve of total topotecan.
    Minami H, Beijnen JH, Verweij J, Ratain MJ.
    Clin Cancer Res; 1996 Jan; 2(1):43-6. PubMed ID: 9816088
    [Abstract] [Full Text] [Related]

  • 4. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG.
    Cancer Chemother Pharmacol; 1995 Jan; 36(6):463-72. PubMed ID: 7554037
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
    van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, Maes RA, Beijnen JH.
    Cancer Chemother Pharmacol; 1995 Jan; 35(3):237-45. PubMed ID: 7805183
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
    Wall JG, Burris HA, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G.
    Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R.
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM.
    Cancer Chemother Pharmacol; 1998 Feb; 41(6):464-8. PubMed ID: 9554590
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ.
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
    O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, Chen TL, Sartorius S, Grochow LB.
    J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
    Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF.
    Cancer Chemother Pharmacol; 1996 Dec; 37(3):195-202. PubMed ID: 8529278
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.
    Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL.
    Cancer Res; 1994 Oct 01; 54(19):5118-22. PubMed ID: 7923128
    [Abstract] [Full Text] [Related]

  • 20. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
    Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verweij J.
    Br J Cancer; 1996 May 01; 73(10):1268-71. PubMed ID: 8630291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.